BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20220313T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20221106T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20230312T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20231105T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20230905T165451Z
CREATED:20230905T165351Z
LAST-MODIFIED:20230905T165451Z
UID:59051-1699747200-1700092799@globalbiodefense.com
SUMMARY:APHA 2023 Annual Meeting & Expo
DESCRIPTION:The 2023 Annual Meeting of the American Public Health Association (APHA 2023) will be held 12-15 November in Atlanta\, Georgia. \nThis year’s premier public health event will be held both in-person and via live and recorded on-demand virtual sessions. \nTopics and sessions highlighted by include: \n\nBuilding partnerships to solve public health emergencies\nAssessing the performance of posterior oral and nasal swabs in a point-of-care tests for SARS-CoV-2\nSupporting equitable public health solutions with saliva-based testing – an innovative\, low-cost\, and scalable testing methodology\nRisk of invasive bacterial infections in under-immunized febrile patients between 2 and 36 months old presenting to the emergency department\nA retrospective geospatial study of chronic wasting disease in Kansas\nQMRA as a tool for probabilistic risk assessment of legionella in drinking and building water distribution systems\nHuman pathogenic bacteria in stream sediments: Teaching beginners the microbiological and bioinformatic methods of public health pathogenomics\nEvaluation for efficacy of field point-of-care malaria diagnostic methods in Ethiopia\nPrevalence and factors associated with HIV testing among sexually experienced high school students in U.S.A.\nLegionella in the Built Environment:  Emerging Research\, Practices\, and Policies\nApplication of systems thinking to investigating and managing legionella risk in cooling towers: Examples from the city and state of New York\nAn integrated vector management program for the prevention and control of the Aedes aegypti mosquito in Puerto Rico\nGut feelings: Investigating diarrhea etiology in low-and middle-income country (LMIC) children\nInsurance coverage and hepatitis b vaccination among Chinese American adults: An analysis of national health interview survey data\nDrug-resistant tuberculosis: A reflection on the development of contemporary treatment policy\nIdentifying the behavioral and social drivers for under-immunized or zero-dose vaccination of children in urban communities of Kathmandu\, Nepal\nDigital health literacy assessment: Insights into the challenges of health informatics in Ukraine\nFactors associated with COVID-19 health misinformation and vaccine hesitancy among hispanic adults in southern California\nPerceived impact of COVID-19 on parental vaccine hesitancy and pediatrician vaccination recommendation behavior\nEffect of positive emotions on vaccine hesitancy: An experimental study with vaccine-hesitant individuals\nUnderstanding geographical information systems (GIS) and its public health informatics applications\nThreats to public health workers\nHarnessing AI for public health preparedness\nLeveraging data to increase supply chain resilience\n\nPlease visit APHA’s Annual Meeting & Expo website to register.
URL:https://globalbiodefense.com/event/apha-2023-annual-meeting-expo/
LOCATION:Georgia World Congress Center\, 285 Andrew Young International Blvd NW\, Atlanta\, GA\, 30313\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231113
DTEND;VALUE=DATE:20231115
DTSTAMP:20231017T165957Z
CREATED:20231016T173338Z
LAST-MODIFIED:20231017T165957Z
UID:59385-1699833600-1700006399@globalbiodefense.com
SUMMARY:BARDA Industry Day - BID2023
DESCRIPTION:The annual BARDA Industry Day (BID) conference will be held 13-14 November 2023 in Washington DC and via virtual participation. \nBID2023: Driving Innovation for Preparedness & Response will feature presentations from BARDA leadership\, U.S. government partners\, and industry on medical countermeasure (MCM) priorities and public health innovation. Attendees will also have an informal opportunity to interact with BARDA and ASPR teams and identify areas of potential collaboration in the field of MCM research and development. \nThe event lineup will have an assortment of BARDA program briefings\, guest speakers\, networking opportunities\, and specialized breakout sessions. Content will focus on BARDA’s efforts to collaborate across government and industry to continually innovate MCMs to address current and future health security threats. \nBARDA’s Influenza and Emerging Infectious Diseases Division (IEIDD) will give a broad ranging presentation on BARDA’s strategy for vaccine development through licensure including harmonized clinical trials\, centralized immune endpoint assays\, determination of correlates of protection\, lessons learned from the COVID-19 vaccine portfolio\, and assay-generated data for accelerated decision making. \nBARDA’s Division of Chemical\, Biological\, Radiological\, And Nuclear (CBRN) Countermeasures will provide an overview of its strategic priorities for branch and division level efforts. Among these priorities include CBRN’s plans to expand the nation’s capabilities to respond to any CBRN health security incident\, whether naturally occurring or intentional. Following the presentations\, a moderated Q&A panel will provide a deeper dive into how division-level priorities can shape medical countermeasure development going forward. \nBARDA program representatives\, industry partners\, and developers will provide an overview of animal models developed in laboratories of network performers funded through the Biological\, Chemical\, and Radiological Indefinite Delivery/Indefinite Quantity (ID/IQ) contract. In addition\, selected product developers funded by BARDA’s nonclinical network will share information on the use of animal models in efforts to license products for use against biodefense threats. \nBARDA’s Biopharmaceutical Manufacturing Preparedness (BioMaP) program has a three-pronged approach to address key vaccine manufacturing gaps to bring the nation up to the speed and scale required for future public health emergencies. In this session\, the BioMaP team will discuss these three components: the BioMaP-Consortium\, the Exercise (BioMaP-X)\, and the BioMaP Workforce Development (BioMaP-W). Join BARDA’s Pharmaceutical Countermeasures Infrastructure Division (PCI) to learn about these different aspects of the BioMaP program. \nSpeakers from the U.S. Food and Drug Administration’s (FDA) Medical Countermeasures Initiative will also address the coordination of emergency activities involving products regulated by the FDA’s Center for Drug Evaluation and Research (CDER)\, Center for Biologics Evaluation and Research (CBER)\, and Center for Devices and Radiological Health (CDRH). \nThe Division of Chemical\, Biological\, Radiological and Nuclear (CBRN)\, Division of Research\, Innovation and Ventures (DRIVe)\, and Division of Nonclinical Development (DNCD) will discuss microphysiological systems (MPS)/organ chips and how it aligns with BARDA’s portfolio. \nLearn more about BARDA Ventures – Global Health Investment Corporation (GHIC) partnership and join a discussion with GHIC on investment focus\, priorities\, and the landscape of venture investment in global health security. In addition\, learn more about the case study with Cytovale and Endpoint Health demonstrating how BARDA Ventures complements BARDA’s other investment vehicles to support MCM development and commercialization. \nA session on host-based diagnostics in sepsis will illuminate the strategic value of Host-Based Diagnostics (HBDs) in the infectious disease space and how to build a community around demonstrating the clinical utility of HBDs and streamlining their adoption and integration into practice. \nUncover BARDA’s latest initiative in clinical trial innovation pertaining to decentralized trials – the Decentralized Clinical Operations for Healthcare and Research (D-COHRe) strategic partnership. Topics include information on D-COHRe and BARDA’s fundamental interagency work towards advancing pandemic preparedness. \nPlease visit Medicalcountermeasures.gov to register. \n 
URL:https://globalbiodefense.com/event/barda-industry-day-bid2023/
LOCATION:Grand Hyatt Washington\, 1000 H St NW\, Washington DC\, 20001\, United States
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2023/10/barda-industry-day-2023.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231114
DTEND;VALUE=DATE:20231119
DTSTAMP:20231028T204037Z
CREATED:20230422T182706Z
LAST-MODIFIED:20231028T204037Z
UID:57061-1699920000-1700351999@globalbiodefense.com
SUMMARY:AMP 2023 Annual Meeting & Expo
DESCRIPTION:The Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo will be held 14-18 November 2023 in Salt Lake City\, Utah. \nAMP is the leading organization in the field of molecular diagnostics\, and the annual meeting is widely considered the “premier gathering” of molecular professionals. With more than 200 exhibiting companies\, 60 educational sessions\, nearly 400 poster presentations\, and 2\,900+ attendees\, the AMP Annual Meeting & Expo is not to be missed. \nExplore how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care. \nThe event begins November 14 with a Short Course Day\, November 15 is the Corporate Workshop Day. This day features 80+ hours of industry sponsored scientific content. This event is free for Annual Meeting attendees and the local healthcare and scientific communities. November 16-18 contains the Scientific Program. \nPlease visit the AMP 2023 Annual Meeting website for more information and to register.
URL:https://globalbiodefense.com/event/amp-2023-association-molecular-pathology/
LOCATION:Salt Palace Convention Center\, 100 S W Temple St\, Salt Lake City\, UT\, 84101\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T130000
DTSTAMP:20231030T224910Z
CREATED:20231030T224910Z
LAST-MODIFIED:20231030T224910Z
UID:59422-1700049600-1700053200@globalbiodefense.com
SUMMARY:Negotiating the Pandemic Treaty: Challenges for Consensus and Equity
DESCRIPTION:The Center for Emerging Infectious Diseases (CEID) will host the Negotiating the Pandemic Treaty: Challenges for Consensus and Equity event on 15 November 2023 in Boston\, MA and via webcast. \nThis event features guest lecture by Adam Kamradt-Scott\, PhD. \nProfessor Adam Kamradt-Scott is the Dr Jiang Yanyong Visiting Professor of Global Health Security at the Harvard T.H. Chan School of Public Health. Adam’s research\, teaching\, and policy engagement work explores how governments and multilateral organisations respond to adverse health events such as epidemics\, pandemics\, and emerging health and security challenges. His most recent research has focused on civil-military cooperation in health and humanitarian crises\, and the adoption of international legal instruments for health. \nPrior to entering academia\, Adam’s background includes having worked as a health professional specializing in emergency care and clinical risk management\, a political adviser\, and a public servant in national pandemic preparedness\, and he holds formal academic qualifications in health\, international relations\, and international law. More recently\, he has served as a consultant to the Australian Government and the World Bank on pandemic preparedness and the COVID-19 response\, and he is continuing to advise the Australian Government on the latest proposed changes to the International Health Regulations and the pandemic treaty. \nAdam is the co-founder and convenor of the Global Health Security conferences and currently serves as the Chair of the Board of Directors for the Global Health Security Network\, a multidisciplinary professional association dedicated to promoting evidence-based policies to improve health outcomes. \nRegister to attend the lecture in person or via Zoom.
URL:https://globalbiodefense.com/event/negotiating-the-pandemic-treaty-challenges-for-consensus-and-equity/
LOCATION:Boston University\, 72 East Concord Street R-103\, Boston\, MA\, 02118\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231115T120000
DTEND;TZID=America/New_York:20231115T133000
DTSTAMP:20231102T173613Z
CREATED:20231102T172619Z
LAST-MODIFIED:20231102T173613Z
UID:59439-1700049600-1700055000@globalbiodefense.com
SUMMARY:Charting a Responsible Future in AI & Biosecurity: Enabling Safe Innovation and Governance
DESCRIPTION:The National Academies’ Health and Medicine Division’s Forum on Microbial Threats and the Division of Earth and Life Studies’ Board on Life Sciences will host a webinar on November 15 on Charting a Responsible Future in AI & Biosecurity. \nThis is the second of two sessions bringing together technology developers\, researchers\, and policymakers working at the intersection of foundation model-based artificial intelligence (AI) and biological research to explore the impact of these technologies on innovation\, potential biosecurity risks\, and promising solutions. \nHighlighted agenda items and strategic questions include: \n\nWhat are the risk concerns and challenges from the legal perspective?\nLayered approach to considering policy options\, connecting to benchmarks (e.g.\, functional characterizations of biological applications and tools for their capabilities)\, and building in evaluations to define the characteristics of the tools\nLeveraging foundation models for pandemic preparedness\, rapid development of countermeasures against emerging threats\nWhat still needs to be defined to enable further discussions on regulation?\nWhat are approaches that can be taken to think about regulation and safety?\n\nThe first session on November 6 examined the technological capabilities and bridging the need for risk management between developers and policymakers. \nPlease visit the National Academies’ AI & Biosecurity Webinar Registration (Forum Microbial Threats) website to register. \n\nMeeting Materials\n\n\n\n AI and Biosecurity Webinar_Background Material \nAI and Biosecurity Webinar_Virtual Attendance Best Practices
URL:https://globalbiodefense.com/event/charting-a-responsible-future-in-ai-biosecurity-enabling-safe-innovation-and-governance/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231128T100000
DTEND;TZID=America/New_York:20231128T110000
DTSTAMP:20231117T215300Z
CREATED:20231117T215300Z
LAST-MODIFIED:20231117T215300Z
UID:59502-1701165600-1701169200@globalbiodefense.com
SUMMARY:Bolivian and Argentinian Hemorrhagic Fevers
DESCRIPTION:Join the National Emerging Special Pathogens Training and Education Center (NETEC) for a webinar on Argentinian hemorrhagic fever (AHF) and Bolivian hemorrhagic fever (BHF) on November 28. \nAHF and BHF are zoonotic diseases with the potential for human-to-human transmission. During this webinar\, guest presenters will describe the epidemiology of AHF and BHF cases\, risk factors\, clinical presentations and management\, and review a public health program model for arenavirus control. Interpretation services will be provided during the event. \nPANELISTS \nAnabel Sinchi\, MD\, MPH\nCristian Castellón Gutierrez\, MD\nMaria (Gaby) Frank\, MD\, FACP\, SFHM – Moderator \nContinuing education credits will be provided for this activity. \nPlease visit NETEC for more information.
URL:https://globalbiodefense.com/event/bolivian-and-argentinian-hemorrhagic-fevers/
LOCATION:https://unmc.zoom.us/webinar/register/WN_HZluRLZcSWK7Kwy-SeI12Q?mc_cid=e4abb4c1d3#/registration/
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T104500
DTEND;TZID=America/New_York:20231205T150000
DTSTAMP:20231202T164659Z
CREATED:20231202T164659Z
LAST-MODIFIED:20231202T164659Z
UID:59526-1701773100-1701788400@globalbiodefense.com
SUMMARY:Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health
DESCRIPTION:The Bipartisan Commission on Biodefense will host a public meeting on Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health in Washington DC on 5 December 2023. \nThis meeting will focus on addressing vulnerabilities in biodefense in the wake of the COVID-19 pandemic. Topics to be discussed include biodefense policies and activities at the Department of Defense\, federal stockpile evaluation and decision-making for smallpox medical countermeasures\, needed authorities of the Centers for Disease Control and Prevention\, and the need for better national leadership of our biodefense in light of its performance during the COVID-19 pandemic. \n“Ongoing conflicts abroad – including the recent onset of war between Israel and Hamas – and the persistent biological weapons aspirations of enemy nations highlight the need for continued vigilance\, reflection\, and improvement in our ability to address biological threats\,” said former U.S. Senator and Commission Co-Chair Joe Lieberman. “The Department of Defense released the results of their Biodefense Posture Review in August\, with dozens of recommendations for enhancing the protection of warfighters\, situational awareness of the threat\, and support for civilian authorities. The Commission is especially interested in learning at this meeting from Assistant Secretary of Defense Rosenblum more about the Biodefense Council that the Department stood up to facilitate implementation of these recommendations and enhance coordination across the Department.” \nThe meeting will feature remarks by: \n\nThe Honorable Deborah G. Rosenblum\, Assistant Secretary of Defense for Nuclear\, Chemical\, and Biological Defense Programs\, Department of Defense\nThe Honorable W. Craig Vanderwagen\, Managing Director\, East West Protection\, LLC\, and former Assistant Secretary for Preparedness Response\, Department of Health and Human Services\nJulie L. Gerberding\, MD\, MPH\, CEO\, Foundation for the National Institutes of Health\, and former Director\, Centers for Disease Control and Prevention\nJeff Reczek\, Director\, Washington Office\, Centers for Disease Control and Prevention\nLaura Efros\, PhD\, Vice President\, U.S. Government Affairs\, Bavarian Nordic\nPaul Williams\, Senior Vice President\, Products Business\, Emergent BioSolutions\nJay Varma\, MD\, Executive Vice President and Chief Medical Officer\, SIGA Technologies\, Inc.\n\n“Our former colleagues on Capitol Hill continue to debate how best to address the biological threat\,” said former Congressman and meeting Co-Chair Fred Upton. “As Congress considers federal roles and responsibilities\, and as our Commission reassesses our 2015 National Blueprint for Biodefense\, strong leadership and additional authorities are required to solve the problems that arose during the COVID-19 pandemic and better defend the Nation against biological weapons from enemy nations and terrorist organizations.” \nPlease visit the Bipartisan Commission on Biodefense Meeting the Moment: Biodefense Policy\, Procurement\, and Public Health event page to register. This meeting will not be live-streamed.
URL:https://globalbiodefense.com/event/meeting-the-moment-biodefense-policy-procurement-and-public-health/
LOCATION:Convene DC\, 600 14th Street NW\, Suite 600\, Washington DC\, DC\, 20005\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231206T060000
DTEND;TZID=America/New_York:20231206T070000
DTSTAMP:20231202T161805Z
CREATED:20231202T154243Z
LAST-MODIFIED:20231202T161805Z
UID:59522-1701842400-1701846000@globalbiodefense.com
SUMMARY:AMR One Health Priority Research Agenda: Transmission
DESCRIPTION:A webinar on the One Health Priority Research Agenda for AMR will be held 6 December 2023\, part of a series hosted by the Quadripartite organizations. This session will focus on transmission. \nThe Quadripartite organizations\, made up of the Food and Agriculture Organization of the United Nations (FAO)\, United Nations Environment Programme (UNEP)\, World Health Organization (WHO)\, and the World Organisation for Animal Health (WOAH)\, established the Quadripartite Technical Group and developed the One Health Priority Research Agenda for AMR (AMR-OHPRA) a joint initiative to assist in directing and catalyzing scientific interest and financial investments for AMR priority research across sectors for countries and funding bodies. \n\n\nThe research agenda also serves as a guide to prevent and mitigate AMR within the One Health approach that will help policymakers\, researchers\, and a multidisciplinary scientific community to work together on solutions. \nThe webinar will include a panel discussion on the challenges and opportunities that this Agenda brings to the One Health community and how this agenda can attract and motivate donors\, the scientific community\, and governments to support research addressing the specific areas identified on Transmission in the AMR-OHPRA. \nHighlighted agenda items include: \nOpening remarks – George Matheu\, WHO \nAMR-OHPRA Transmission pillar – Francesca Latronico\, FAO \nDiscussion panel: \n\nHeike Schmitt – Delft Technical University\, The Netherlands\nPhil Taylor – Centre for Agriculture and Bioscience International\, UK\nRungtip Chuanchuen – Chulalongkorn University\, Thailand\nAmit Khurana – Centre for Science and Environment\, India\nPilar Donado – Colombian Corporation of Agricultural Research (AGROSAVIA)\, Columbia\n\nRegister for the webinar here.
URL:https://globalbiodefense.com/event/amr-one-health-priority-research-agenda-transmission/
LOCATION:
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240108
DTEND;VALUE=DATE:20240111
DTSTAMP:20240106T224238Z
CREATED:20231206T221746Z
LAST-MODIFIED:20240106T224238Z
UID:59580-1704672000-1704931199@globalbiodefense.com
SUMMARY:Biotech Showcase 2024
DESCRIPTION:The Biotech Showcase 2024 investor conference for innovators will be held 8-10 January 2024 in San Francisco and 16-17 January for virtual participants \nThis premier investor conference is a platform for private and micro-mid-cap biotechnology companies\, offering a unique opportunity to showcase innovations and engage one-to-one with investors and biopharmaceutical executives. \nIn attendance at Biotech Showcase\, you’ll find not only executives from biopharmaceutical and life science companies but also private and public company presentations\, investors\, sector analysts\, bankers and industry professionals. \nThrough its specialized showcases—DigiMed Showcase and Seed Showcase—the event also provides convenient access to the life science ecosystem. \nBiotech Showcase is a co-produced by Demy-Colton and EBD Group\, two organizations with a combined experience of over 50 years in producing high-quality programs that foster growth in the biotechnology sector and broader life science industry. \nPlease visit the Biotech Showcase 2024 website for more information.
URL:https://globalbiodefense.com/event/biotech-showcase-2024/
LOCATION:Hilton San Francisco Union Square\, 333 O'Farrell St\, San Francisco\, CA\, 94102\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240115
DTEND;VALUE=DATE:20240120
DTSTAMP:20240111T192843Z
CREATED:20240111T192843Z
LAST-MODIFIED:20240111T192843Z
UID:59610-1705276800-1705708799@globalbiodefense.com
SUMMARY:World Economic Forum Annual Meeting
DESCRIPTION:The 54th Annual Meeting of the World Economic Forum will be held 15-19 January 2024 in Davos-Klosters\, Switzerland. The meeting is accessible to the wider public through the livestreaming of over 200 sessions. \nThis Annual Meeting will welcome over 100 governments\, all major international organizations\, 1000 Forum’s Partners\, as well as civil society leaders\, experts\, youth representatives\, social entrepreneurs\, and news outlets. \nThe meeting convenes under the theme Rebuilding Trust\, accessible to the wider public with over 200 sessions livestreamed – the full programme is available here. \nHighlighted agenda sessions include: \n\nFacing a World Without Antibiotics\nWhen Climate Impacts Your Health\nSupply Chains of the Future\nClimate and Nature: Seed Capital Needed\nProtecting the Vulnerable Online\nSpecial Address by Volodymyr Zelenskyy\, President of Ukraine\nGenerative AI: Steam Engine of the Fourth Industrial Revolution?\n\n\nLast year at Davos\, the word ‘polycrisis‘ was on everybody’s lips as leaders deliberated the cascading and connected crises of the moment. Today\, even as we turn our attention to new crises\, the old ones persist. \n\n\n“At a time when global challenges require urgent solutions\, innovative public-private collaboration is necessary to convert ideas into action. The Forum provides the structure for developing research\, alliances and frameworks that promote mission-driven cooperation throughout the year\,” said Børge Brende\, President\, World Economic Forum. \nMore than 300 public figures will participate this year\, including more than 60 heads of state and government. There will be strong representation from all key regions of the world. \n\nAn estimated 1\,600 business leaders\, including 800-plus of the world’s top CEOs and chairs from the World Economic Forum’s Members and Partners\, will participate. There will also be more than 150 Global Innovators\, Tech Pioneers and Unicorns who are transforming industries. \n\n\nMore than 200 members of the Forum’s Global Shapers\, Young Global Leaders and Social Entrepreneurs communities will join to showcase local innovations and solutions. Also taking part in the meeting will be more than 150 experts and heads of the world’s leading universities\, research institutions and think tanks. More than 40 labour\, nongovernment organization and religious leaders from civil society will take part as well. \n\n\nHeads of civil society organizations include: Kirsten Schuijt\, Director-General\, WWF International; David Miliband\, President\, International Rescue Committee; Luc Triangle\, General Secretary\, International Trade Union Confederation; Tirana Hassan\, Executive Director\, Human Rights Watch. \n\n\nPlease visit the World Economic Forum 2024 Annual Meeting website for more information.
URL:https://globalbiodefense.com/event/world-economic-forum-annual-meeting/
LOCATION:https://www.weforum.org/events/world-economic-forum-annual-meeting-2024/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240122
DTEND;VALUE=DATE:20240128
DTSTAMP:20240111T173857Z
CREATED:20240111T173650Z
LAST-MODIFIED:20240111T173857Z
UID:59597-1705881600-1706399999@globalbiodefense.com
SUMMARY:WHO Executive Board Meeting
DESCRIPTION:The World Health Organization will convene the 154th session of the WHO Executive Board in Geneva from 22-27 January 2024. \nThe Executive Board is composed of 34 technically qualified members elected for three-year terms. The annual Board meeting is held in January when the members agree upon the agenda for the World Health Assembly (scheduled for May 2024) and the resolutions to be considered by the Health Assembly\, including the 2025-2028 Programme of Work\, sustainable financing\, and global health emergency priorities and processes. \nHighlighted agenda items (links below) include the Draft Global Action Plan for Infection Prevention and Control; Immunization Agenda; Antimicrobial resistance operational priorities 2025-2035; Smallpox eradication: destruction of variola virus stocks; Public health emergencies: preparedness and response; Strengthening the global architecture for health emergency preparedness\, prevention and response and resilience. \nProceedings will be webcast and recorded for on-demand viewing. \n\nThe Executive Board\n\n\n\nChair and Officers of the Executive Board \nComposition of the Executive Board \nEB154/1\nProvisional agenda \nEB154/1 (annotated)\nProvisional agenda (annotated) \nEB154/3\nReport of the regional committees to the Executive Board \nEB154/5\nReport of the Standing Committee on Health Emergency Prevention\, Preparedness and Response \nEB154/6\nUniversal health coverage \nEB154/7\nFollow-up to the political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases\nPrevention and management of noncommunicable diseases\, promotion of mental health and well-being\, and treatment and care of mental health conditions \nEB154/8\nDraft global action plan for infection prevention and control\nDraft global action plan and monitoring framework \nEB154/8 Add.1\nDraft global action plan on infection prevention and control\nDraft global action plan and monitoring framework: minimum requirements for IPC programmes at national and health care facility levels \nEB154/9\nImmunization Agenda 2030\nProgress towards global immunization goals and implementation of the Immunization Agenda 2030 \nEB154/10\nEnd TB Strategy\nProgress in implementing the global strategy and targets for tuberculosis prevention\, care and control after 2015 (the End TB Strategy) \nEB154/11\nRoad map for neglected tropical diseases 2021–2030 \nEB154/12\nAcceleration towards the Sustainable Development Goal targets for maternal health and child mortality \nEB154/13\nAntimicrobial resistance: accelerating national and global responses\nWHO strategic and operational priorities to address drug-resistant bacterial infections in the human health sector\, 2025–2035 \nEB154/14\nWHO’s work in health emergencies\nPublic health emergencies: preparedness and response \nEB154/15\nWHO’s work in health emergencies\nStrengthening the global architecture for health emergency preparedness\, prevention and response and resilience \nEB154/16\nImplementation of resolution WHA75.11 (2022) \nEB154/17\nGlobal Health and Peace Initiative \nEB154/18\nPoliomyelitis\nPoliomyelitis eradication \nEB154/19\nPoliomyelitis\nPolio transition planning and polio post-certification \nEB154/20\nSmallpox eradication: destruction of variola virus stocks \nEB154/21\nSocial determinants of health\nProgress of the World Report on Social Determinants of Health Equity \nEB154/23\nWell-being and health promotion \nEB154/24\nClimate change\, pollution and health\nImpact of chemicals\, waste and pollution on human health \nEB154/25\nClimate change and health \nEB154/27\nFinancing and implementation of the Programme budget 2022–2023 and outlook on financing of the Programme budget 2024–2025 \nEB154/28\nDraft fourteenth general programme of work \nEB154/29 Rev.1\nSustainable financing: WHO investment round \nEB154/32\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nSecretariat implementation plan on reform \nEB154/33\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nStrengthening WHO’s budgetary\, programmatic and financing governance: follow-up to the implementation of decision EB152(15) (2023) \nEB154/33 Add.1\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProposals for improving the effectiveness of the WHO Governing bodies \nEB154/33 Add.2\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProject plan: implementation of digital solutions for interactions between the Secretariat and Member States on matters related to the governing bodies \nEB154/33 Add.3\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nCost recovery mechanisms for voluntary contributions – an update \nEB154/34\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance \nEB154/34 Add.1\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nFollow-up to decision WHA69(8) (2016)\, operative paragraph (10) \nEB154/34 Add.2\nMatters emanating from the Agile Member States Task Group on Strengthening WHO’s Budgetary\, Programmatic and Financing Governance\nProposed methodology for costing new initiatives/programmes \nEB154/36\nEngagement with non-State actors\nReport on the implementation of the Framework of Engagement with Non-State Actors \nEB154/37\nEngagement with non-State actors\nNon-State actors in official relations with WHO \nEB154/37 Add.1\nFinancial and administrative implications for the Secretariat of decisions proposed for adoption by the Executive Board \nEB154/38\nNomination and appointment of Regional Directors\nProcess for the election of Regional Directors \nEB154/39\nProvisional agenda of the Seventy-seventh World Health Assembly \nEB154/50\nReport on meetings of expert committees and study groups\nReport by the Director-General \nEB154/50 Add.1\nReport on meetings of expert committees and study groups\nExpert advisory panels and committees and their membership
URL:https://globalbiodefense.com/event/who-executive-board-meeting/
LOCATION:https://www.who.int/about/accountability/governance/executive-board/executive-board-154th-session
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240123
DTEND;VALUE=DATE:20240124
DTSTAMP:20240623T231054Z
CREATED:20240111T194643Z
LAST-MODIFIED:20240623T231054Z
UID:59614-1705968000-1706054399@globalbiodefense.com
SUMMARY:OECD High-Level Policy Forum: Better Policies for More Resilient Health Systems
DESCRIPTION:The Organisation for Economic Co-operation and Development (OECD) will host a Ministerial Meeting on Better Policies for More Resilient Health Systems on 23 January 2024 in Paris\, France and via virtual broadcast. \nAs the world emerges from the biggest public health emergency in more than a century\, it is clear that there are lessons to be learned. The COVID-19 crisis exposed significant weaknesses in health systems\, calling for urgent action to ensure that they more resilient to future shocks. At the same time\, global megatrends such as climate change\, demographic change and increased digitalisation will likely have significant implications for health and healthcare in the years to come. \nIn January 2024\, Health Ministers from OECD and partner countries will come together to discuss the legacy and lessons learned from the COVID-19 crisis\, the health policy challenges that lie ahead\, and the actions needed to address them. The meeting will be Chaired by Belgium\, with Australia\, Chile\, Germany\, Norway and Slovenia serving as Vice-Chairs. \nHighlighted agenda items include: \n\nBolstering public health: Healthy populations for more resilient health systems\nThe future of digital health after COVID-19\nThe future of pharmaceutical policy\n\n“Our health systems have continuously improved over recent decades\, both in terms of investment and outcomes. Many have worked tirelessly to make that happen. Nevertheless\, the COVID-19 pandemic was a sobering reminder: fundamental challenges on issues such as workforce\, prevention and health promotion\, mental health\, inequalities and the supply chain of medical goods continue to put pressure on our health systems\,” notes Frank Vandenbroucke\, Chair of the 2024 OECD Health Ministerial Meeting. “If we want to make our health systems more future-proof\, we must take these challenges seriously – especially in the context of rapid social\, technological and environmental change.” \nThe OECD High-Level Policy Forum on The Future of People-Centred Health Innovation will take place on 22 January 2024\, on the eve of the OECD Health Ministerial Meeting. The Forum will explore policies and priorities for adopting new innovations into health systems and is being organised by the OECD\, in collaboration with the Commonwealth Fund and the Health Foundation and in partnership with Financial Times Live. \nPlease visit the OECD Ministerial Meeting page for more information and to register.
URL:https://globalbiodefense.com/event/oecd-high-level-policy-forum-better-policies-for-more-resilient-health-systems/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240130T133000
DTEND;TZID=America/New_York:20240130T144500
DTSTAMP:20240623T230714Z
CREATED:20240126T225333Z
LAST-MODIFIED:20240623T230714Z
UID:59713-1706621400-1706625900@globalbiodefense.com
SUMMARY:Kazakhstan’s Actions to Address Nuclear and Biological Risks
DESCRIPTION:The Carnegie Endowment and the Council on Strategic Risks will host a panel on Kazakhstan’s increasingly global role in the changing threat landscape of weapons of mass destruction on 30 January 2024 in Washington DC and by webcast. \nUpon the 1991 collapse of the Soviet Union\, Kazakhstan found itself in possession of the world’s fourth-largest nuclear weapons stockpile and the former union’s most significant biological weapons factory. Kazakhstan’s subsequent decision to return and dismantle these weapons has solidified its position as a leader in nuclear and biological risk reduction. For the last thirty years\, Kazakhstan’s actions have served as a core model for regional and international security. \nThe discussion will feature Kazakhstan’s Ambassador to the United States of America Yerzhan Ashikbayev\, the Honorable Andrew Weber\, and Dr. Toghzan Kassenova. It will be moderated by Shannon Green\, senior fellow at the Council on Strategic Risks. \nPlease visit the Carnegie Endowment’s Kazakhstan’s Actions to Address Nuclear and Biological Risks event page to RSVP.
URL:https://globalbiodefense.com/event/kazakhstans-actions-to-address-nuclear-and-biological-risks/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240201T120000
DTEND;TZID=Europe/Paris:20240201T130000
DTSTAMP:20240125T192454Z
CREATED:20240125T192454Z
LAST-MODIFIED:20240125T192454Z
UID:59695-1706788800-1706792400@globalbiodefense.com
SUMMARY:WHO Update on COVID-19
DESCRIPTION:A World Health Organization (WHO) update on COVID-19 will be held 1 February 2024 via an EPI-WIN webinar. \nCOVID-19 remains a major public health concern. WHO experts will address what variants are circulating\, their risk and impact\, and what can be done to prevent and protect against infections\, severe disease\, post-COVID-19 condition and deaths. The experts will also address common concerns from the public. \nSpeakers: \n\nDr Maria Van Kerkhove\, Director (a.i.)\, Department of Epidemic and Pandemic Preparedness and Prevention (EPP)\, WHO\nDr Janet Diaz\, Unit Head\, Clinical Management\, WHO\nDr Lorenzo Subissi\, Technical Officer\, EPP\, WHE\, WHO (TBC)\nMs Vicky Houssiere\, Technical Officer\, Risk Communication and Community Engagement (RCCE)\, WHE\, WHO\nMs Shagun Khare\, Communications Officer\, WHE\, WHO\n\nPlease visit the EPI-WIN webinar: WHO update on COVID-19 event page to register. This webinar will be livestreamed on the WHO YouTube channel.
URL:https://globalbiodefense.com/event/who-update-on-covid-19/
LOCATION:https://who.zoom.us/webinar/register/WN_ULS7nOrqRCaw2H9lUZmO7w#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240202
DTEND;VALUE=DATE:20240203
DTSTAMP:20240201T190248Z
CREATED:20240201T190201Z
LAST-MODIFIED:20240201T190248Z
UID:59787-1706832000-1706918399@globalbiodefense.com
SUMMARY:Meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures
DESCRIPTION:This is a closed session\, virtual meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures. \nThe meeting is an activity of an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine charged with conducting a study to examine lessons learned from the recent COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the current state of research\, development\, and stockpiling of smallpox medical countermeasures (MCMs). \nThe committee will consider how the COVID-19 pandemic and the mpox multi-country outbreak can inform improvements to smallpox readiness and response\, including the availability of smallpox MCMs and the ability to meet potential demand. \nThe committee will further examine the current state of MCMs for the diagnosis\, prevention\, and treatment of smallpox\, including: \n\nHow the mpox outbreak altered assumptions about the efficacy and utility of smallpox MCMs\nThe continued role of live Variola virus for research and public health purposes\nImplications for the composition of smallpox MCMs in the U.S. Strategic National Stockpile (SNS)\n\nThe benefits and risks of scientific and technological advances on smallpox readiness and response will be addressed and the committee will identify key priorities in research and development of smallpox MCMs. \nBuilding on the Institute of Medicine’s previous reports\, Assessment of Future Scientific Needs for Live Variola Virus (1999) and Live Variola Virus: Considerations for Continuing Research (2009)\, and a review of existing literature\, analyses\, and other expert and public input\, the committee will develop a report with its findings and conclusions on priorities for additional research or activities to improve the U.S. Government readiness and response posture against smallpox\, and on the composition of the SNS to ensure appropriate smallpox MCM response options. \nPlease visit the National Academies’ Meeting 5 of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures event page for more information.
URL:https://globalbiodefense.com/event/meeting-of-the-committee-on-the-current-state-of-research-development-and-stockpiling-of-smallpox-medical-countermeasures/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20240205T170000
DTEND;TZID=America/Denver:20240205T183000
DTSTAMP:20240202T221754Z
CREATED:20240202T221754Z
LAST-MODIFIED:20240202T221754Z
UID:59867-1707152400-1707157800@globalbiodefense.com
SUMMARY:Investigating Public Health Mysteries in a Globalized World
DESCRIPTION:The Scowcroft Institute of International Affairs at the Bush School of Government & Public Service at Texas A&M University will host Katherine Eban as she discusses “Investigating Public Health Mysteries in a Globalized World” on February 5\, 2024\, at 5:30 p.m. at the Annenberg Presidential Conference Center. \nAmericans want high-quality\, affordable medication and safety from infectious diseases. But those public health goals are increasingly impacted by far-distant events\, and far different regulatory cultures from our own. Katherine Eban\, an award-winning investigative journalist\, will describe the challenges and rewards of investigating big public health stories that have international and national security repercussions. \nAbout the speaker: \nKatherine Eban \nKatherine Eban\, an investigative journalist\, is a Vanity Fair special correspondent and Andrew Carnegie fellow. Her reporting on generic drug fraud\, gun trafficking\, coercive CIA interrogations\, and COVID-19’s origins has won international attention and numerous awards\, including from the National Association of Science Writers\, the Overseas Press Club\, Investigative Reporters & Editors and Newswomen’s Club of New York. Her 2019 book\, Bottle of Lies: The Inside Story of the Generic Drug Boom\, was a New York Times bestseller. A Rhodes Scholar educated at Brown University and Oxford University\, she lives in New York with her husband\, two daughters and Newfoundland dog\, Romeo. \nPlease visit the Texas A&M Bush School of Government & Public Service’s Investigating Public Health Mysteries in a Globalized World event page to RSVP.
URL:https://globalbiodefense.com/event/investigating-public-health-mysteries-in-a-globalized-world/
LOCATION:Annenberg Presidential Conference Center\, 1002 Bush Drive West\, College Station\, TX\, 77845\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240206
DTEND;VALUE=DATE:20240208
DTSTAMP:20240201T205734Z
CREATED:20240201T202039Z
LAST-MODIFIED:20240201T205734Z
UID:59796-1707177600-1707350399@globalbiodefense.com
SUMMARY:Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions - Third Meeting
DESCRIPTION:This is the third meeting of the committee of experts and will be conducted virtually. The meeting will include a closed and public session. There will be an opportunity for interested stakeholders to share public comments with the committee on February 7\, 2024 at 12:00 p.m. \nPublic comments will provide the committee with additional insight into key issues related to the study’s statement of task. These include\, but are not limited to: \n\nThe use of regulatory flexibilities and supplementary data (e.g.\, natural history studies and patient registries) when evaluating the safety and efficacy of drugs for rare diseases and conditions\nFDA and EMA engagement of people with lived experience when developing guidance\, policies\, and programs.\n\nPublic comments\, alongside other materials stakeholders have shared\, will be reviewed by the committee\, and may help inform committee deliberations on the statement of task. All comments and materials shared with the committee will be made publicly available in accordance with institutional policies. \nPlease visit NASEM’s Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information on public comments for this meeting. \nOPEN SESSION AGENDA HIGHLIGHTS \n\nLongitudinal trial design\nMaster protocols for drug development trials\nExternal controls for drug development trials\nConsiderations for pediatric trials: caregiver perspective\nConsiderations for pediatric trials: regulatory science perspective\nConsiderations for pediatric trials: industry perspective\nExpanded access programs\nPatient registries and natural history data\nPatient experience data\nModel-informed drug development\nAnalysis methods – causal inference\nFlexibilities applied at FD\n\nABOUT THE COMMITTEE \nIn response to a Congressional request\, an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine is conducting a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. \nThe committee will evaluate: \n\nFlexibilities\, authorities\, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions;\nThe consideration and use of supplemental data submitted during review processes in the United States and the European Union\, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions.\nAn assessment of collaborative efforts between United States and European Union regulators related to: product development programs under review; policies under development and those recently issued; and scientific information related to product development or regulation.\n\nBased on its information gathering and internal deliberations\, the committee will develop a report with its findings\, conclusions\, and recommendations for actions that Congress\, federal agencies\, the pharmaceutical industry\, and nongovernmental organizations can take to support collaborative efforts. \nPlease visit the National Academies’ Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information. \nThe Fourth Meeting of the committee will be held 3-4 April 2024. \nThe Fifth Meeting of the committee will be held 23-24 May 2024.
URL:https://globalbiodefense.com/event/processes-to-evaluate-the-safety-and-efficacy-of-drugs-for-rare-diseases-or-conditions-in-the-united-states-and-the-european-union/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240207T100000
DTEND;TZID=America/New_York:20240207T110000
DTSTAMP:20240125T183458Z
CREATED:20240125T182836Z
LAST-MODIFIED:20240125T183458Z
UID:59690-1707300000-1707303600@globalbiodefense.com
SUMMARY:What's Next for the Pandemic Financing Agenda?
DESCRIPTION:A virtual event featuring an expert panel focused on What’s Next for the Pandemic Financing Agenda? will be held 7 February 2024. \nAs the world approaches the four-year anniversary of the start of the COVID-19 pandemic\, questions remain as to whether we are more prepared and ready than before. A recently published CGD working paper indicated a substantial risk of occurrence of future pandemics. Yet the financing tools for preparedness and response remain immature\, if not neglected. The world still needs faster\, larger\, and clearer financing tools for pandemics. In this webinar\, we review the ongoing problem of gaps in the global pandemic risk financing architecture in the aftermath of the G20 Pandemic Financing report and G7 Nagasaki Health Ministers’ Communiqué\, and propose specific policy recommendations for world leaders and multilateral and bilateral donors to consider in 2024. \nSPEAKERS \n\nRuchir Agarwal\, Research Fellow\, Harvard Kennedy School; Non-resident Fellow\, Center for Global Development\nNita Madhav\, Senior Director\, Head of Epidemiology & Modeling\, Ginkgo Bioworks\nCarolyn Reynolds\, Co-Founder\, Pandemic Action Network\nCristina Stefan\, Lead Risk Finance Advisor\, Centre for Disaster Protection\n\nMODERATOR \n\nVictoria Fan\, Senior Fellow\, Center for Global Development\n\nThe virtual event\, co-hosted by CGD\, Ginkgo Bioworks\, the Pandemic Action Network\, and the Centre for Disaster Protection\, will begin with short presentations from each speaker\, followed by a discussion among the panelists and an audience Q&A. \nPlease visit the What’s Next for the Pandemic Financing Agenda? event page to register and for more information. \n 
URL:https://globalbiodefense.com/event/whats-next-for-the-pandemic-financing-agenda/
LOCATION:https://www.youtube.com/watch?v=SEyOTTRAyD8
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240208
DTEND;VALUE=DATE:20240209
DTSTAMP:20240201T184853Z
CREATED:20240201T184853Z
LAST-MODIFIED:20240201T184853Z
UID:59785-1707350400-1707436799@globalbiodefense.com
SUMMARY:Enhancing Biotechnology Innovation and Applications for National Security – First Meeting of Experts
DESCRIPTION:The National Academies will convene a meeting of experts on 8 Feb 2024 to focus on ways to foster a research and development network in the United States that drives biotechnology innovation and applications. \nThis meeting will be held in a hybrid setting (Washington DC and online). \nThis is the first of a series of meetings of experts\, organized under the auspices of the Standing Committee on Advances and National Security Implications of Transdisciplinary Biotechnology\, which will bring together gatherings of cross-sector experts to discuss key topics at the intersection of national security and transdisciplinary biotechnology research and development. \nThe forthcoming second meeting of experts will focus on understanding future defense needs and ways to communicate those needs to the research community.  The third meeting of experts will focus on understanding the regulatory processes and needs in the United States to enhance development of innovative biotechnologies for defense and subsequently\, to transition defense-specific biotechnologies and services to other sectors. \nEach meeting will highlight how more general concepts relate to specific biotechnologies using two illustrative examples: \n\nUse of artificial intelligence in biotechnology research and development\nExperimental/laboratory automation in biotechnology and development\n\nThe effort is sponsored by the National Security Commission on Emerging Biotechnology. \nPlease visit the  Enhancing Biotechnology Innovation and Applications for National Security – First Meeting of Experts.
URL:https://globalbiodefense.com/event/enhancing-biotechnology-innovation-and-applications-for-national-security-first-meeting-of-experts/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240208T080000
DTEND;TZID=America/New_York:20240208T170000
DTSTAMP:20240201T220044Z
CREATED:20240201T215837Z
LAST-MODIFIED:20240201T220044Z
UID:59814-1707379200-1707411600@globalbiodefense.com
SUMMARY:Why Indoor Chemistry Matters Prioritizing Indoor Chemistry Research - Workshop 2
DESCRIPTION:A National Academies committee of experts on Emerging Science on Indoor Chemistry will meet for a workshop on 8 February 2024 to discuss ways to support and prioritize indoor chemistry research. \nThe event is a hybrid in-person (Washington DC) and virtual format. \nThis event aims to discuss the following topics: \n\nOutcomes and recommendations from the National Academies consensus report Why Indoor Chemistry Matters.Special focus will be given to Recommendation 8 “ Given the challenges\, complexity\, knowledge gaps\, and importance of indoor chemistry\, federal agencies and others that fund research should make the study of indoor chemistry and its impact on indoor air quality and public health a national priority”.\nEmerging or impactful areas of indoor chemistry research.\nExamine current funding opportunities available for indoor chemistry research; identify how sustained support for the field can be achieved in the near future.\nA major goal on this workshop is to encourage more partnerships with funding agencies\, foundations\, and NGOs to strengthen investment in indoor chemistry research.\n\nHighlighted agenda topics include: \nWhy Indoor Chemistry Matters: Select Recommendations \n\nVicki H. Grassian\, PhD\, Chair\, Department of Chemistry and Biochemistry\, University of California\, San Diego\n\nAssessing Chemical Complexity in Indoor Environments \n\nJonathan Abbatt\, PhD\, Professor\, University of Toronto\nRobin E. Dodson\, ScD\, Associate Director of Research Operations and Research Scientist\, Silent Spring Institute\nVito Ilacqua\, PhD\, Acting Director of the Center for Scientific Analysis\, Office of Radiation and Indoor Air (ORIA)-Office of Air and Radiation (OAR)\, U.S. Environmental Protection Agency\nXiaoyu Liu\, PhD\, Senior Physical Scientist\, U.S. Environmental Protection Agency\nBarbara Turpin\, PhD\, Professor\, University of North Carolina\, Chapel Hill\n\nGermicidal UV Radiation\, Unintended Chemistry: \n\nDelphine Farmer\, PhD\, Professor\, Colorado State University\nMichael F. Link\, Physical Scientist\, Engineering Laboratory\, National Institute of Standards and Technology (NIST)\nPaula Olsiewski\, PhD\, Contributing Scholar\, Johns Hopkins Center for Health Security\nRichard Williamson\, Program Director\, Far-UVC\, Blueprint Biosecurity\n\nHow Do we Strengthen the Handshake Between IAQ and Exposure Science/Cognition\, Health and Well-Being: \n\nAntonia Calafat\, PhD\, Chief\, Organic Analytical Toxicology Branch\, Centers for Disease Control and Prevention\nElaine Cohen-Hubal\, PhD\, Senior Science Advisor\, U.S. Environmental Protection Agency\nLCDR Jason Ham\, PhD\, Research Scientist\, Health Effects Laboratory Division (HELD)\, Chemical and Biological Monitoring Branch (CBMB)\, National Institute for Occupational Safety and Health (NIOSH)\nKrystal Pollitt\, PhD\, PEng\, Associate Professor of Epidemiology\, Yale School of Public Health (YSPH)\nTreye Thomas\, PhD\, Lead Toxicologist and Program Manager\, Chemicals\, Nanotechnology and Emerging Materials (CNEM) Program\, Office of Hazard Identification and Reduction\, Consumer Product Safety Commision (CPSC\n\nBuildings Impact on Chemistry \n\nMark Hernandez\, PhD\, Professor\, University of Colorado\, Boulder\nJeffrey Siegel\, PhD\, Professor\, University of Toronto\nBrett Singer\, PhD\, Staff Scientist and Principal Investigator (PI)\, Energy Technologies Area\, Lawrence Berkeley National Laboratory\nDavid Rowson\, Director Indoor Environments Division\, Environmental Protection Agency\nBrian Gilligan\, PEng\, SCPM \, Deputy Director\, Office of Federal High Performance Green Buildings\, General Services Administration\n\nRESOURCES: \nWhy Indoor Chemistry Matters (2022) \nPeople spend the vast majority of their time inside their homes and other indoor environments where they are exposed to a wide range of chemicals from building materials\, furnishings\, occupants\, cooking\, consumer products\, and other sources. Despite research to date\, very little is known about how exposures to indoor chemicals across complex chemical phases and pathways affect human health. The COVID-19 pandemic has only increased public awareness of indoor environments and shed light on the many outstanding questions about how best to manage chemicals indoors. \nPROJECT GOALS: \nThis study will examine the state of science regarding chemicals in indoor air. A team of scientific experts will focus on under-reported chemical science discoveries and how these findings shine light on the link between chemical exposure\, air quality\, and human health. The final report will explore potential opportunities for new scientific research. It will also identify what research will be most critical to understanding the chemical composition of indoor air and adverse exposures. The environments in this study will be limited to non-industrial exposure within buildings. \nPlease visit the Why Indoor Chemistry Matters Workshop 2: Prioritizing Indoor Chemistry Research event page to register.
URL:https://globalbiodefense.com/event/why-indoor-chemistry-matters-prioritizing-indoor-chemistry-research-workshop-2/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T110000
DTEND;TZID=America/New_York:20240215T160000
DTSTAMP:20240202T000503Z
CREATED:20240202T000503Z
LAST-MODIFIED:20240202T000503Z
UID:59822-1707994800-1708012800@globalbiodefense.com
SUMMARY:Forum on Medical and Public Health Preparedness for Disasters and Emergencies
DESCRIPTION:The Forum on Medical and Public Health Preparedness for Disasters and Emergencies will convene again on 15 February 2024. \nIn this meeting\, Forum members will: \n\nIdentify the seminal social and behavioral sciences (SBS) lessons learned from COVID-19 and other past public health emergencies\nExplore how SBS lessons\, concepts\, and theories can be leveraged to inform and be incorporated in future medical and public health preparedness and response efforts\nDiscuss receive updates\, and provide input on current and planned Forum activities and other National Academies activities of interest.\n\nFormed in 2007\, the Forum on Medical and Public Health Preparedness for Disasters and Emergencies convenes and engages leaders at federal\, state\, local\, tribal\, and territorial levels representing government\, non-profit\, and for-profit sectors to improve the nation’s medical and public health preparedness for\, response to\, and recovery from disasters and emergencies\, including emerging threats. \nRecent work of the Forum includes: \n\nMedical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships\nFuture of the Nation’s Laboratory Systems for Health Emergency Response\n Future Planning for the Public Health Emergency Preparedness Enterprise: Lessons Learned from the COVID-19 Pandemic\nApplying Lessons Learned from COVID-19 Research and Development to Future Epidemics\nAccelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance\nEvolving Crisis Standards of Care and Lessons Learned\nCOVID-19: Disaster Preparedness and Vulnerable Populations\nEnhancing Private Sector Readiness for 21st Century Health Threats\nEngaging Private Sector Healthcare Systems in Building Capacity to Respond to Threats to the Public’s Health and National Security\nThe Future of Disaster Health Volunteerism\n\nPlease visit the National Academies’ Forum on Medical and Public Health Preparedness for Disasters and Emergencies – February 2024 Meeting  website for more information. \n 
URL:https://globalbiodefense.com/event/forum-on-medical-and-public-health-preparedness-for-disasters-and-emergencies/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T120000
DTEND;TZID=America/New_York:20240215T130000
DTSTAMP:20240125T224115Z
CREATED:20240125T223922Z
LAST-MODIFIED:20240125T224115Z
UID:59701-1707998400-1708002000@globalbiodefense.com
SUMMARY:The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques
DESCRIPTION:The Homeland Defense & Security Information Analysis Center (HDIAC) will host a webinar on The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques on 15 February 2024. \nGiven the current global shift toward symmetrical warfare\, major powers and nonstate proxies are developing radical leveling and emerging technology for use as “deterrence leveraging” in nonkinetic and kinetic engagements. \nAlthough regnant treaties and conventions are postured to govern chemical and biological weapons\, novel advances in genetics\, synthetic biology\, and neuroscience can enable side-stepping such international regulatory constraints when coupled with big data and cyberscientific tools and methods. These advances can also afford rapid scientific and technological progress in ways that pose a clear and present threat to global biosecurity and defense. \nIn this webinar\, Dr. James Giordano will present an overview of current and emerging developments in CB-DCST; describe trajectories for their deterrent applications in nonkinetic and/or kinetic engagements; address ethico-legal issues relevant to their research\, use\, and governance; and propose a paradigm for realistic approach to informing surveillance\, forecasting\, and regulatory control. \nABOUT THE SPEAKER : Dr. James Giordano\, Ph.D.\, MPhil \nDr. James Giordano is Pellegrino Center professor of neurology and biochemistry\, chief of the Neuroethics Studies Program\, and codirector of the Project on Brain Science and Global Health Law and Policy at Georgetown University Medical Center. He serves as senior bioethicist of the Defense Medical Ethics Center\, Uniformed Services University of Health Sciences; Stockdale distinguished fellow of science\, technology\, and ethics at the U.S. Naval Academy; and non-resident senior fellow of the Simon Center for the Professional Military Ethic at the U.S. Military Academy\, West Point\, NY. \nPlease visit HDIAC’s The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques on 15 February 2024.
URL:https://globalbiodefense.com/event/the-clear-and-present-threat-of-chem-bio-and-data-and-cyberscientific-and-technological-cb-dcst-tools-and-techniques/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240222
DTSTAMP:20240207T184247Z
CREATED:20240207T184123Z
LAST-MODIFIED:20240207T184247Z
UID:59952-1708387200-1708559999@globalbiodefense.com
SUMMARY:CWMD/MCDC Winter Medical & WMD Countermeasure Symposium
DESCRIPTION:The CWMD/MCDC: 2024 Winter Medical & WMD Countermeasure Symposium will be held 20-21 February 2024 in Baltimore\, Maryland. \nHosted by the Countering Weapons of Mass Destruction Consortium (CWMD) and the Medical CBRN Defense Consortium (MCDC)\, the event will feature sessions to interact with leads from key programs\, for example: \n\nJPEO Futures\nJoint Project Leads (JPL) PL Enabling Biotechnologies (EB)\nJoint Project Managers (JPM) Special Operations Forces (SOF)\nJoint Project Managers (JPM) Protection\n\nPoster Registration Deadline is 14 February. \nABOUT THE CWMD CONSORTIUM \nThe Countering Weapons of Mass Destruction (CWMD) Consortium is a well-established community of industry\, academia and government focused on rapid prototyping and maturing countering WMD efforts and CBRNE hazard awareness. Through an Other Transaction Agreement with the JPEO-CBRND (Joint Program Executive Office for Chemical\, Biological\, Radiological and Nuclear Defense)\, the CWMD Consortium is accomplishing the counter WMD related prototyping needs of any federal agency. \nThe CWMD scope spans development of PPE\, detection systems\, sensors\, other protection needs\, and situational awareness. These address consequence management/hazard mitigation; threats/vulnerabilities awareness and counter-proliferation technologies/capabilities; arms control technologies; experimentation of emerging technologies and CBRNE technologies to deliver capabilities to the warfighter. \nABOUT THE MEDICAL CBRN DEFENSE CONSORTIUM \nThe Medical CBRN Defense Consortium (MCDC) is a well-established community of industry\, academia\, and government focused on rapid prototyping and maturing medical countermeasures to prevent\, detect and treat exposure to CBRN threats. Through an Other Transaction Agreement with the JPEO-CBRND (Joint Program Executive Office for Chemical\, Biological\, Radiological and Nuclear Defense)\, the MCDC is developing life-saving medical pharmaceutical\, diagnostics and therapeutics to safe-guard and enhance the mission effectiveness of our soldiers. \nThe MCDC scope spans development of medical countermeasure prototypes to include vaccines (COVID-19\, Marburg\, Ebola\, VEE\, VEEV\, Botulinum\, etc.)\, therapeutics (COVID-19\, SNAPP\, small molecule antivirals\, OPNAs\, Smallpox\, MDR Bacterial bio threat pathogens\, Tularemia\, etc.)\, detection/diagnostics (Meliodiosis\, Plague\, CRISPR-based\, man-portable diagnostics systems\, antibody platforms\, etc.)\, autoinjectors (Scopolamine\, Naloxone\, Diazepam\, etc.) and other needs. \nPlease visit the Medical CBRN Defense Consortium site for more information or register here for the CWMD/MCDC Winter Medical & WMD Countermeasure Symposium.
URL:https://globalbiodefense.com/event/cwmd-mcdc-winter-medical-wmd-countermeasure-symposium/
LOCATION:Baltimore Marriott Waterfront\, 700 Aliceanna St\, Baltimore\, MD\, 21202\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240228
DTSTAMP:20240219T192805Z
CREATED:20240202T233915Z
LAST-MODIFIED:20240219T192805Z
UID:59870-1708387200-1709078399@globalbiodefense.com
SUMMARY:The 38th Annual AAAI Conference on Artificial Intelligence
DESCRIPTION:The AAAI-24 Annual Conference on Artificial Intelligence will be held 20-27 February in Vancouver\, Canada. \nThe purpose of the AAAI conference series is to promote research in Artificial Intelligence (AI) and foster scientific exchange between researchers\, practitioners\, scientists\, students\, and engineers across the entirety of AI and its affiliated disciplines. AAAI-24 will feature technical paper presentations\, special tracks\, invited speakers\, workshops\, tutorials\, poster sessions\, senior member presentations\, competitions\, and exhibit programs\, and a range of other activities to be announced. \nHighlighted topics and presentations include: \n\nML+Optimization: Driving Social Impact in Public Health and Conservation\nDeploying ADVISER : Impact and Lessons from using Artificial Intelligence for Child Vaccination Uptake in Nigeria\nOutlier Ranking for Large-Scale Public Health Data\nGeometric ML: from Euclid to Drug Design\nGenerating Novel Leads for Drug Discovery Using LLMs with Logical Feedback\nAngle Robustness Unmanned Aerial Vehicle Navigation in GNSS-Denied Scenarios\nGeometric-Facilitated Denoising Diffusion Model for 3D Molecule Generation\nProtein 3D Graph Structure Learning for Robust Structure-Based Protein Property Prediction\nDual-Channel Learning Framework for Drug-Drug Interaction Prediction via Relation-Aware Heterogeneous Graph Transformer\nGxVAEs: Two Joint VAEs Generate Hit Molecules from Gene Expression Profile\nPSC-CPI: Multi-Scale Protein Sequence-Structure Contrasting for Efficient and Generalizable Compound-Protein Interaction Prediction\nA Multi-Modal Contrastive Diffusion Model for Therapeutic Peptide Generation\nRegulating AI: Applying Insights from Behavioural Economics and Psychology to the Application of Article 5 of the EU AI Act\n\nPlease visit the AAAI-24 Conference website for more information and to register.
URL:https://globalbiodefense.com/event/the-38th-annual-aaai-conference-on-artificial-intelligence/
LOCATION:Vancouver Convention Center\, 1055 Canada Pl\, Vancouver\, British Columbia\, V6C 0C3\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Zurich:20240220T090000
DTEND;TZID=Europe/Zurich:20240220T103000
DTSTAMP:20240219T010614Z
CREATED:20240219T010514Z
LAST-MODIFIED:20240219T010614Z
UID:60060-1708419600-1708425000@globalbiodefense.com
SUMMARY:CIABT and Biological Risks
DESCRIPTION:Advances in biotechnology generate new opportunities\, but also create certain risks in terms of dual use of biological and toxin agents and with respect to compliance with the 1972 Convention on the Prohibition of Biological Weapons (CIABT). \nThis is the first event in a series of French-speaking meetings on disarmament in 2024 which will present the CIABT and provide a more in-depth analysis of contemporary biological risks\, including in relation to artificial intelligence and cyber. The event will also provide insight into the ongoing work of the CIABT Working Group established by the 9th Review Conference in November 2022. \nThe event is open to all interested participants. The United Nations Institute for Disarmament Research (UNIDIR) encourages the participation of French-speaking representatives and experts specialized in or interested in issues related to CIABT and/or biological risks. This event will take place in French. No interpretation into other UN languages ​​will be provided. \nPROGRAMME \n\nWelcome Address: Dr. Robin Geiss \, Director\, UNIDR\nIntroductory remarks : Mr. Guillaume Ollagnier \, Director of Strategic Affairs\, Security and Disarmament at the Ministry of Europe and Foreign Affairs of France\, and HE Camille Petit \, Permanent Representative of France to the Conference on Disarmament\nPresentation of the CIABT : Mr. Remi Bacouillard \, Political Affairs Officer\, CIABT Implementation Support Unit\, Office for Disarmament Affairs (UNODA)\nOverview of scientific and technological advances : Dr. Anna Laura Ross \, Head of the Emerging Technologies Unit of the Division of Science of the World Health Organization (WHO)\, and Ms. Louison Mazeaud \, Associate Researcher\, Weapons Program mass destruction\, UNIDIR\nPerspectives on the ongoing work of the CIABT Working Group : Ms. Barbara Belkior \, Minister-Counsellor\, Permanent Representation of Brazil to the Conference on Disarmament\nConcluding remarks : HE Salomon Eheth\, Permanent Representative of Cameroon to the United Nations Office and other international organizations in Geneva\n\nThe event will be moderated by the Permanent Observer of the International Organization of la Francophonie (OIF) to the United Nations Office in Geneva\, HE Henri Monceau. \nPlease visit the UNIDR website for registration.
URL:https://globalbiodefense.com/event/ciabt-and-biological-risks/
LOCATION:Palais des Nations\, 1211 Geneva 10\, Geneva\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240220T120000
DTEND;TZID=America/Los_Angeles:20240220T130000
DTSTAMP:20240202T212828Z
CREATED:20240202T212828Z
LAST-MODIFIED:20240202T212828Z
UID:59865-1708430400-1708434000@globalbiodefense.com
SUMMARY:Threat-Agnostic Biodefense: Assessing the Zoonotic Risk of Pre-emergent Viruses
DESCRIPTION:The Pacific Northwest National Laboratory will host a webinar on “Assessing the Zoonotic Risk of Pre-emergent Viruses” on 20 February 2024 as part of the the Advancing Threat Agnostic Biodefense Webinar Series. \nThese webinars bring together like-minded science and policy members of the biodefense community to discuss relevant research activities as well as barriers and enablers of a threat agnostic approach. \nFeatured speaker: Tony Goldberg\, PhD\, Professor\, School of Veterinary Medicine\, University of Wisconsin-Madison \nExploration of the “virosphere” is in its golden age. The sheer number of new viruses discovered daily\, and the fact that most cannot be cultured\, creates enormous about where to allocate attention and resources. It is not an intractable problem\, however\, to distinguish those few viruses that are likely to emerge as zoonoses from the many others that are not. \nThis talk describes two diametric approaches to addressing this problem. The first approach involves a field-to-lab investigative methodology that\, when combine with biologically informed predictive computational models\, can assess the zoonotic risk of viruses that have not yet been identified in humans. \nThe second approach relies on the power of modern methods in anthropology and ethnography to identify zoonotic transmission pathways\, even before the identification of any pathogens that might traverse those pathways. A unifying example is simian hemorrhagic fever virus and its relatives in the family Arteriviridae\, which cause important animal diseases but have never been documented to infect humans. Both approaches identify these viruses as high-risk pre-emergent zoonoses. \nPlease visit PNNL for more information and to register.
URL:https://globalbiodefense.com/event/threat-agnostic-biodefense-assessing-the-zoonotic-risk-of-pre-emergent-viruses/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240222T090000
DTEND;TZID=America/New_York:20240222T160000
DTSTAMP:20240202T211124Z
CREATED:20240202T210750Z
LAST-MODIFIED:20240202T211124Z
UID:59861-1708592400-1708617600@globalbiodefense.com
SUMMARY:PACCARB Public Meeting
DESCRIPTION:The 24th Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) public meeting will be held virtually on February 22\, 2024. \nThis will be the second of two meetings to address the task provided to the PACCARB by the Secretary of HHS to address antimicrobial resistance globally. The focus of the meeting will be on international implementers and the gaps\, challenges\, and opportunities they see to combat AMR globally – specifically focusing on low- and middle-income countries. \nMeetings of the PACCARB are open to the public\, and virtual meetings can be accessed through the webcast. Registration to attend is not required but is encouraged. Attendees may also directly address the council on topics of antimicrobial resistance during public meetings. To provide written comments\, please e-mail your comments to CARB@hhs.gov. Written comments must be sent in by midnight February 15\, 2024 and should be limited to no more than one page. All public comments received prior to the deadline will be provided to the PACCARB council members. \nMeeting times are tentative and subject to change. Please visit HHS’ PACCARB website for the most current information.
URL:https://globalbiodefense.com/event/paccarb-public-meeting/
LOCATION:
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240223
DTEND;VALUE=DATE:20240224
DTSTAMP:20240218T175243Z
CREATED:20240218T174811Z
LAST-MODIFIED:20240218T175243Z
UID:60021-1708646400-1708732799@globalbiodefense.com
SUMMARY:Rapid Access to Products in Development (RAPID) Virtual Industry Day
DESCRIPTION:A Joint Industry Day for the Rapid Access to Products in Development (RAPID) program to be held virtually on 23 Feb 2024. \nThe Joint Program Executive Office for Chemical\, Biological\, Radiological\, and Nuclear Defense\, Enabling Biotechnologies (JPEO-CBRND-EB)\, develops\, manufactures and delivers safe and effective Medical Countermeasures (MCMs) for preparedness\, prevention\, protection\, response\, and recovery from CBRN threats. \nThe Rapid Access to Products in Development (RAPID) program is an integrated defense system composed of both physical MCM storage and fielding capabilities and a readily accessible information warehouse and sharing system (the RAPID Database). \nThe purpose of this Industry Day is to identify industry partners and capabilities to develop a RAPID Database capable of storing and organizing complex data and information related to CBRN MCMs such that it is intuitively accessible by a variety of end users during urgent planning and response situations. \nThe Database is intended to provide actionable information to assist CCMD-level decision makers when evaluating a RAPID MCM for potential administration to US warfighters; and JPEO- and CBDP-level decision makers when determining portfolio investment strategies or rapid response adjustments based on changing circumstances. \nThis Industry Day will include presentation by JPL EB as well as opportunities for industry partners to present their capabilities in one-on-one breakout sessions with representatives from the Government agencies. Industry partners will update Government stakeholders\, partners\, and end users on current efforts and capabilities. \nCompanies that wish to attend must register no later than 19 Feb 2024. More information is available at SAM.gov Notice ID W911SR-24-S-RAPID.
URL:https://globalbiodefense.com/event/medical-countermeasures-rapid-access-to-products-in-development-rapid-virtual-industry-day/
LOCATION:
CATEGORIES:Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240224
DTEND;VALUE=DATE:20240229
DTSTAMP:20240202T041837Z
CREATED:20240202T041825Z
LAST-MODIFIED:20240202T041837Z
UID:59826-1708732800-1709164799@globalbiodefense.com
SUMMARY:Pittcon 2024
DESCRIPTION:Pittcon 2024 will be held 24-28 February 2024 in San Diego\, California. \nThis 75th edition of the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon) is for anyone who develops\, buys\, or sells laboratory equipment\, performs physical or chemical analyses\, develops analysis methods\, or manages these scientists. \nPittcon is a dynamic\, international conference and exposition on laboratory science\, a venue for presenting the latest advances in analytical research and scientific instrumentation\, and a platform for continuing education and science-enhancing opportunity. \nHighlighted agenda and short course topics include: \n\nPoint-of-use Raman spectroscopic characterization of pathogens\nThermally Robust Biomimetic Substitutes to Metalloenzymes for Rapid Hydrolytic Degradation and Electrochemical Field Detection of Chemical Warfare Agents\nStrategy and Instrumentation for Safety Protection of Personnel Working on Ships for Maritime Chemical Threat Assessment and Response\nChemical Spill and Chemical Fires in East Palestine\, Ohio: Chemical Fate and Exposure Pathways\nField-deployable Biosensors for Rapid Characterization of Microbiomes\nNuclear Forensics: Analytical Chemistry Combating Nuclear Terrorism\nLabel-Free Lab on a Chip Device for Purification and Characterization of Small Extracellular Vesicles\nFighting Bacteria with Micromotors\nTargeted and Untargeted Analysis for Rapid Response Following Disasters\nOvercoming Challenges in Pharmaceutical Development Using Novel Analytical Approaches\nApplication of 2DLC to novel therapeutics\nModified Membranes for Rapid Monoclonal Antibody Capture\, Digestion\, and Analysis\nBiomarker Detection using Microfluidics\nHandheld Near-Infrared Spectroscopy: Anywhere\, Anytime by Anybody\nIntroduction to Quantitative Spectroscopy for Near Infrared and Raman Instrumentation\nIntroduction to Solid State NPR Spectroscopy\nFundamentals and Recent Developments of X-Ray Photoelectron Spectroscopy\nThe Art of Structure Elucidation of Small Molecules Using Mass Spectrometry\nIndustrial Problem-Solving Using Surface FTIR Techniques\nEffective Technical Communication for Analytical Chemists\nMethod Translation and Modelling in Gas Chromatography\nThermal Gel Electrophoresis to Streamline Biological Characterizations\n\nPlease visit the Pittcon 2024 website for more information and to register to attend.
URL:https://globalbiodefense.com/event/pittcon-2024/
LOCATION:San Diego Convention Center\, 111 West Harbor Drive\, San Diego\, CA 92101\, 92101\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240224T190000
DTEND;TZID=America/New_York:20240224T213000
DTSTAMP:20240202T001437Z
CREATED:20240202T001437Z
LAST-MODIFIED:20240202T001437Z
UID:59824-1708801200-1708810200@globalbiodefense.com
SUMMARY:An Enemy of the People: A Public Health Project
DESCRIPTION:LabX – a program of the National Academy of Sciences – in partnership with Cultural Programs of the NAS\, present An Enemy of the People\, featuring performances by acclaimed actors David Strathairn (Nomadland)\, Keith David (Nope)\, Brían F. O’Byrne (The Wonder)\, and Jay O. Sanders (True Detective) as well as public health leaders Anthony Fauci (Former Director\, National Institute of Allergy and Infectious Diseases)\, Francis Collins (Former Director\, National Institutes of Health)\, Keshia Pollack Porter (Chair\, Department of Health Policy and Management\, Johns Hopkins Bloomberg School of Public Health)\, Gloria Addo-Ayensu (Director of Health\, Fairfax County Health Department)\, Ruth Faden (Founder\, Johns Hopkins Institute of Bioethics)\, Victor Dzau (President\, National Academy of Medicine)\, Nancy Kass (Deputy Director of Public Health at the Johns Hopkins Institute of Bioethics)\, Vivian Pinn (Senior Scientist Emerita at the NIH Fogarty International Center) and more! \nTogether they will perform dramatic readings of scenes from Henrik Ibsen’s 1882 play An Enemy of the People to help frame powerful\, guided audience discussions aimed at generating connection\, understanding\, compassion\, moral repair\, and much-needed healing. \nAn Enemy of the People tells the story of a doctor who discovers the water supply in his small\, rural town has been poisoned by a tannery. Despite his efforts to convey the truth to the public\, the doctor fails to save his community from environmental disaster and is ultimately scapegoated for his whistleblowing. An Enemy of the People was first performed in Norway in 1882\, and yet it speaks to the present moment as if it were written for our times — to the corrosive influence of power and money in politics\, the distortions of the media\, and the many other challenges to public health in our culture today\, especially during times of crisis. \nJoin NAS for an evening of profound exploration\, thought-provoking dialogue\, and shared intellectual engagement. \nPresented by Theater of War Productions and LabX – A Program of the National Academy of Sciences in partnership with Cultural Programs of the National Academy of Sciences. Adapted\, directed\, and facilitated by Bryan Doerries. \nPlease visit the National Academies’ An Enemy of the People: A Public Health Project to register to attend.
URL:https://globalbiodefense.com/event/an-enemy-of-the-people-a-public-health-project/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
END:VCALENDAR